-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Currently, in patients with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic stem cell transplantation (Allo-HSCT), there is a lack of safe and effective rescue therapy.
stem cell
From September 2017 to October 2019, the study included 11 patients with B-cell acute lymphoblastic leukemia who relapsed after Allo-HSCT treatment.
The results showed that 8 patients (72.
In summary, the results of this prospective study show that allogeneic donor-derived anti-CD19 CAR T cell therapy is a safe and effective rescue plan, suitable for relapsed/refractory B-cell acute lymphocytes after allogeneic hematopoietic stem cell transplantation Patients with leukemia.
Original source:
Jingsheng Hua, et al.
ncbi.
nlm.
nih.
gov/32507386/" target="_blank" rel="noopener">Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed / Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation
in this message